Drugs / PD-1Ab21-BCMA CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07489534 | Sep 2025 → Jul 2027 expected | plasma cell myeloma | Daihong Liu | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PD-1Ab21-BCMA CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07489534 ↗ |
| Modality | Cell therapy | “BCMA CAR-T cells” NCT07489534 ↗ |